Cardiac Amyloidosis in Spinal Stenosis: the CASS-study

Status Active, not recruiting

Clinical Trial Summary

Background: A significant portion of cardiac amyloidosis patients have a 5 to 10 years prior history of spinal canal stenosis, reflecting a diagnostic red flag that should raise suspicion for amyloidosis presence. Mild troponin release and NT-proBNP elevation, both serum cardiac biomarkers, often coincide with cardiac amyloidosis. Early cardiac amyloidosis treatment improves survival, warranting timely diagnosis. Study aim: to test a prospective screening strategy, based on serum cardiac biomarkers, to increase early detection of cardiac amyloidosis in patients with spinal canal stenosis. Design: Single-centre prospective observational non-interventional diagnostic study. Methods: Consecutive patients during a one-year period in AZ Sint-Jan Bruges, without known cardiac amyloidosis history and scheduled for spinal canal stenosis surgery, will have cardiac evaluation including serum cardiac biomarker (high-sensitive troponin T and NT-proBNP) assessment, electrocardiography and transthoracic echocardiography. During surgery, all patients will undergo ligamentum flavum biopsy to evaluate presence and burden of transthyretin amyloid deposition (Congo-red staining and immune histochemistry). All patients with suspicion for cardiac amyloidosis will undergo further diagnostic testing (including laboratory test and bone scintigraphy). A chronologic cascade screening process will be used starting with abnormal serum cardiac biomarkers (high-sensitive troponin T ≥ 14 ng/ml and/or NT-proBNP > 125 pg/ml), followed by electrocardiography, transthoracic echocardiography and finally ligamentum flavum biopsy results. The diagnostic performance of this biomarker-based strategy will be compared to electrocardiography, echocardiography and ligamentum flavum biopsy. Conclusion: It is hypothesised that serum cardiac biomarker testing in patients undergoing spinal canal stenosis surgery represents a simple and valuable prospective screening strategy for early detection of cardiac amyloid(osis).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04653675
Study type	Observational
Source	AZ Sint-Jan AV
Contact
Status	Active, not recruiting
Phase
Start date	January 1, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04459169` - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting	`NCT03029026` - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting	`NCT06034405` - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting	`NCT04915235` - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting	`NCT02966522` - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis	Phase 2
Terminated	`NCT03333551` - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy	Phase 4
Recruiting	`NCT04105634` - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT	Early Phase 1
Recruiting	`NCT05139797` - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting	`NCT05593679` - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting	`NCT04146415` - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera	N/A
Recruiting	`NCT03626584` - PET/MR Imaging In Patients With Cardiac Amyloidosis
Recruiting	`NCT04856267` - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Completed	`NCT03119558` - PET/MRI Evaluation of Cardiac Amyloid	Early Phase 1
Recruiting	`NCT02798705` - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting	`NCT04387344` - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting	`NCT06129656` - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated	`NCT01683825` - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography	Phase 4
Withdrawn	`NCT04363294` - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot	N/A
Not yet recruiting	`NCT04661800` - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis	N/A
Terminated	`NCT03232632` - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cardiac Amyloidosis in Spinal Stenosis: the CASS-study — CASS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms